Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies [0.03%]
将诊断检测纳入肿瘤无关型疗法经济学评价中
Tamás Zelei,Gábor Kovács,Shirin Ashrafganjouei et al.
Tamás Zelei et al.
Introduction: Tumor-agnostic treatments represent paradigm shift in oncology, targeting specific genetic mutations irrespective of the tumor's anatomical origin. This personalized approach relies on companion diagnostic t...
Proposed method for economic evaluation based on basket trials: a case study of pembrolizumab [0.03%]
基于篮式试验的经济评价方法及其帕博利珠单抗案例分析
Marzieh Nosrati,Hossein Vatankhah,Mahdi Asfia et al.
Marzieh Nosrati et al.
Background: Precision medicine's emphasis on genetic profiles rather than diseases has reshaped oncology trials, prioritizing biomarker-specific approaches named basket trials. They involve heterogeneous populations, nece...
QUALITATIVE RESEARCH ON THE ACCEPTANCE OF EVOLVING EVIDENCE FOR HTA BODY APPROVAL OF INNOVATIVE HEALTH TECHNOLOGIES IN SELECTED EUROPEAN COUNTRIES [0.03%]
欧洲选定国家卫生技术评估机构接受新兴证据以审批创新医疗技术的定性研究
E Reith,L Maas,A Joos et al.
E Reith et al.
Objective: With increasing efforts of streamlining market access of innovative drugs, current acceptance of health technology assessment (HTA) bodies on non-traditional trial designs is still unclear. The aim of this stud...
Economic and healthcare resource utilization for hereditary transthyretin amyloidosis with polyneuropathy in Spain: real-world insights from early-stage patients and mutation carriers [0.03%]
西班牙遗传性转甲状腺素蛋白淀粉样变性的经济和医疗资源利用：来自早期患者和突变携带者的现实世界见解
Fernando Martínez Valle,Lucía Galán Dávila,Juan Buades Reinés et al.
Fernando Martínez Valle et al.
Objective: Variant transthyretin (ATTRv) amyloidosis is a rare genetic multisystem disease inducing progressive morbidity. Evidence about its economic burden is scarce. This study estimated annual use and costs of healthc...
Collaborative economic tools for prevention strategies: case of the EQUIPT model [0.03%]
协作经济工具在预防策略中的应用——以EQUIPT模型为例
Kei Long Cheung,Mickaël Hiligsmann
Kei Long Cheung
Cost-effectiveness of ruxolitinib in Singapore for patients with chronic graft-versus-host disease [0.03%]
鲁索利替尼治疗慢性移植物抗宿主病患者的成本效益分析
Naren Kumar Surendra,Jiamin Ong,Xin Yi Wong et al.
Naren Kumar Surendra et al.
Objective: To evaluate the cost-effectiveness of ruxolitinib in Singapore for patient with chronic graft-versus-host disease (GVHD) and inadequate response to corticosteroids. ...
Challenges with integrating early-stage cancer trial endpoints into economic models: review of health technology recommendations for adjuvant or neoadjuvant therapies in Canada [0.03%]
加拿大健康技术评估中辅助或新辅助疗法推荐中的早期癌症试验终点纳入经济学模型的挑战综述
Jaclyn M Beca,Stephanie Gosselin,Don Husereau et al.
Jaclyn M Beca et al.
Objectives: Adjuvant and neoadjuvant therapies for early-stage cancers demonstrate early clinical benefit in delaying disease recurrence. Health technology assessments require economic evaluations modeling lifetime diseas...
Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population [0.03%]
西班牙儿童群体中肺炎球菌疫苗接种的20价成本效益分析
Franciso Álvarez García,Federico Martinón-Torres,Valentín Pineda et al.
Franciso Álvarez García et al.
Objectives: We evaluated the cost-effectiveness of implementingdifferent pneumococcal conjugate vaccines (PCV) - 20-valent (PCV20; 3 + 1), 13-valent(PCV13; 2 + 1), and 15-valent (PCV15; 2 + 1) - into the Spanish pediatric...
Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers [0.03%]
理解低风险癌症经济学评价的生存上限及开展和评估经济评价的能力
Xuanqian Xie,Ishita Joshi,Myra Wang et al.
Xuanqian Xie et al.
Background: In most developed countries, overall survival rates for low-riskcancers (e.g. localized prostate and thyroid cancer) are comparable tothose of the general population. The general population's survival rate may...
Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C [0.03%]
阿达格拉西单药或联合西妥昔单抗治疗KRAS G12C突变型结直肠癌患者的成本效益分析
Ruihong Yao,Yao Yao,Xue Teng et al.
Ruihong Yao et al.
Objectives: This study evaluates the cost-effectiveness of adagrasib plus cetuximab in contrast to adagrasib monotherapy in treating colorectal cancer (CRC) patients with mutated KRASG12C from the perspective of healthcar...